The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exploratory biomarker assessment in the Trastuzumab for Gastric Cancer (ToGA) study.
F. Lordick
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Fresenius Biotech; Merck Serono
E. Van Cutsem
Consultant or Advisory Role - Roche
Research Funding - Roche
J. Rüschoff
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - Roche
J. Hill
Employment or Leadership Position - Roche
Other Remuneration - Roche
M. Lehle
Employment or Leadership Position - Roche
A. C. Kiermaier
Employment or Leadership Position - Roche
G. Aprile
No relevant relationships to disclose
Y. Omuro
No relevant relationships to disclose
T. J. Price
Consultant or Advisory Role - Roche (U)
Y. Bang
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche